Graybug Vision, Inc.
Redwood City, CA, US· latest recorded location
Graybug Vision, Inc. is named on 11 US grants and 21 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 11
- Published applications
- 21
- Inventors
- 22
- Granted in 2026 so far
- 0
- Most recent grant
- 31 Jan 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2017 | 1 | 2 |
| 2018 | 4 | 6 |
| 2019 | 2 | 1 |
| 2020 | 0 | 3 |
| 2021 | 1 | 4 |
| 2022 | 1 | 1 |
| 2023 | 2 | 2 |
| 2024 | 0 | 2 |
By publication year.
Technology areas
Share of 32 documents
Recent patents
- Aggregating microparticles for medical therapy31 Jan 2023US 11,564,890 B2
- Drugs and compositions for the treatment of ocular disorders10 Jan 2023US 11,548,861 B2
- Equatorially modified polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates9 Aug 2022US 11,407,781 B2
- Extended release microparticles and suspensions thereof for medical therapy2 Nov 2021US 11,160,870 B2
- Compounds and compositions for the treatment of ocular disorders26 Nov 2019US 10,485,876 B2
- Drugs and compositions for the treatment of ocular disorders21 Mar 2024US 2024/0092745 A1
- Aggregating microparticles for medical therapy8 Feb 2024US 2024/0041783 A1
- Extended release microparticles and suspensions thereof for medical therapy23 Feb 2023US 2023/0056284 A1
- Extended release microparticles and suspensions thereof for medical therapy23 Feb 2023US 2023/0058971 A1
- New equatorially modified polymer linked multimers of guansine-3', 5'-cyclic monophosphates22 Dec 2022US 2022/0402964 A1
Most cited
By later US patents
- Compounds and compositions for the treatment of ocular disorders4US 9,808,531 B22017
- Extended release microparticles and suspensions thereof for medical therapy1US 11,160,870 B22021
- Equatorially modified polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates1US 11,407,781 B22022
- Compounds and compositions for the treatment of ocular disorders1US 9,956,302 B22018